The ESCMID Study Group for Non-Traditional Antibacterial Therapy (ESGNTA) brings together professionals from various expertise dedicated to advancing the use of bacteriophages and other new non-traditional therapeutic approaches to treat infectious diseases. Their mission includes:
Cross-border dialogue: An international survey of regulators on phage therapy.
Alvarez RD, Årdal C, Classen AY, Nagel TE, Ceyssens PJ, German GJ. Int J Antimicrob Agents. 2025 Dec;66(6):107614
Phage therapy.
Mikael Skurnik, Sivan Alkalay-Oren, Maarten Boon, Martha Clokie, Thomas Sicheritz-Pontén,Krystyna Dąbrowska, Graham F. Hatfull, Ronen Hazan, Matti Jalasvuori, Saija Kiljunen, Rob Lavigne, Danish J. Malik, Ran Nir-Paz & Jean-Paul Pirnay. Nature Reviews Methods Primers 2025. 5, Article number: 10
2025 ICM: Role of Unconventional Medications.
Suh GA; ESGNTA; Scobie A; ESGNTA; Piuzzi NS, Bartak V, Anyaehie UE, Arciola CR, Batailler C, Benes M, Binlaksar R, Buttaro M, Damioli LE, de Beaubien BC, Dietz MJ, Doub JB, Elmenawi KA, Falez F, Ferry T; ESGNTA; Goswami K, Kucukdurmaz F, Li B, Metsemakers WJ, Moriarty TF, Saeed M, Shah RP, Springer B, Tootsi K, Tsiridis E, Urish KL. J Arthroplasty. 2025 Oct 31:S0883-5403(25)01395-6
Phages and phage-borne enzymes as new antibacterial agents.
McCallin S, Drulis-Kawa Z, Ferry T, Pirnay JP, Nir-Paz R. Clin Microbiol Infect. 2023;20:S1198-743X(23)00528-1.
Personalized Phage Therapy: Basic Principles of monitoring and treatment: Supplement 5 1 Nov 2023
Nir-Paz R, Iredell J, Suh G, Fabijan AP. Clinical Infectious Diseases, Vol 77, Issue Supplement 5, 1 November 2023.
If you have questions or comments for our study group, we warmly invite you to contact us!
